04.21.26 -- Six Specialized Modalities Testing CDMO Readiness In 2026

Watch as our CGT experts explore the evolving landscape of viral vector manufacturing, overcoming production bottlenecks, and the strategies necessary to bring life-changing therapies to more patients.

Discover how one family's collaboration with a specialized CDMO enabled the rapid development of a life-saving gene therapy for their daughter diagnosed with an ultra-rare disease.

To meet patient demand, advanced therapy manufacturing processes must be commercial ready. CGT sponsors can mitigate risk and protect viability by partnering with a CDMO that prioritizes scalability.

Digital transformation begins with a clear framework. See a model that helps biomanufacturers assess and advance digital capabilities, enabling smarter decisions and long-term innovation.

Accelerate access to high-quality, cost-effective lentiviral vectors with our intensified manufacturing platform, delivering multi-fold yield improvements and scalable, space-efficient production.

As cell and gene therapies continue to advance, a well-integrated analytical framework will be critical for accelerating development timelines and optimizing regulatory submissions.

In this report, view concrete examples of projects across a global network that are contributing to the successful achievement of sustainability goals and aspirations.

Experience the benefits of faster, more effective CAR-T cell production with this innovative three-day short-cycle process, designed to enhance patient treatment outcomes while reducing costs.

By implementing an efficient characterization strategy, researchers can enhance the consistency of allogeneic cell therapy starting material, ultimately leading to improved clinical outcomes.

Fill‑finish is evolving as biologics and advanced therapies shift capacity and sterility needs. Automation, emerging tech, and data‑driven methods are boosting efficiency in aseptic production.

Achieve faster AAV gene therapy progress by adopting a unified platform for manufacturing. Accelerate your program to GMP readiness with up to 9x higher titers and robust, high-quality full capsid yields.

Economic volatility, regulatory uncertainty, and capacity constraints pose major risks to CDMOs, threatening growth, profitability, and long-term sustainability in an increasingly competitive global market.